Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Anderson, Kenneth
Item TypeName
Academic Article Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Academic Article Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Academic Article Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Academic Article A phase 2 study of bortezomib in relapsed, refractory myeloma.
Academic Article A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Academic Article Multiple myeloma: how far have we come?
Academic Article Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Academic Article Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Academic Article Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Academic Article Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Academic Article Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Academic Article The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Academic Article Comparison of twin and autologous transplants for multiple myeloma.
Academic Article Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.
Academic Article Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.
Academic Article The treatment of relapsed and refractory multiple myeloma.
Academic Article Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
Academic Article Multiple myeloma.
Academic Article Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Academic Article A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Academic Article Sequence analysis of ß-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Academic Article Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
Academic Article Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Academic Article Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Academic Article Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Academic Article Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Academic Article Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.
Academic Article Multiple myeloma.
Academic Article Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
Academic Article Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
Academic Article Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.
Academic Article Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Academic Article Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.
Academic Article The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Academic Article Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Academic Article Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Academic Article Emerging trends in the clinical use of bortezomib in multiple myeloma.
Academic Article Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
Academic Article The emerging role of novel therapies for the treatment of relapsed myeloma.
Academic Article A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.
Academic Article Management of relapsed and relapsed/refractory multiple myeloma.
Academic Article Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Academic Article Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Academic Article Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Academic Article Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
Academic Article Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
Academic Article Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.
Academic Article Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Academic Article Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
Academic Article Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
Academic Article Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Academic Article Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Academic Article Multiple myeloma, version 1.2013.
Academic Article Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Academic Article Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Concept Neoplasm Recurrence, Local
Concept Recurrence
Academic Article Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Academic Article The current landscape of multiple myeloma treatment.
Academic Article Oncogenomics to target myeloma in the bone marrow microenvironment.
Academic Article Intracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity.
Academic Article Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Academic Article Therapeutic advances in relapsed or refractory multiple myeloma.
Academic Article Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Academic Article A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Academic Article Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
Academic Article The future of treatment for patients with relapsed/refractory multiple myeloma.
Academic Article Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
Academic Article The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
Academic Article Current treatment landscape for relapsed and/or refractory multiple myeloma.
Academic Article Stem cell transplant for first relapse from the multiple myeloma research foundation.
Academic Article Salvage second hematopoietic cell transplantation in myeloma.
Academic Article Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Academic Article American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Academic Article Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Academic Article VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Academic Article Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.
Academic Article Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.
Academic Article Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Academic Article Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
Academic Article A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
Academic Article Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.
Academic Article Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist.
Academic Article A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Academic Article Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Academic Article Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
Academic Article Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Academic Article Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Search Criteria
  • Recurrence
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.